umifenovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals 4868 131707-25-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • arbidole
  • umifenovir
  • arbidol
an antiviral agent. Although data is limited, in vitro activity against SARS-CoV-1 and SARS-CoV-2 has been reported. The drug has been included in COVID-19 treatment guidelines used in China and Russia.
  • Molecular weight: 477.42
  • Formula: C22H25BrN2O3S
  • CLOGP: 5.50
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 54.70
  • ALOGS: -4.85
  • ROTB: 8

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 60
kinase-selectivity-class AXL,BRAF,EIF2AK3,GRK2,STK33,TEK 6
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 205.56 162.76 62 40 1102190 89526155

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 249.61 121.88 78 43 638257 41982957

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 421.62 169.71 135 100 1500050 109089014

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AX13 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Other antivirals
CHEBI has role CHEBI:22587 antiviral agent

Related Drugs by ATC class:

J05AX Other antivirals 15 drugs
amenamevirbaloxavir marboxilbulevirtideenfuvirtidefavipiravirfostemsaviribalizumabinosine pranobexlenacapavirletermovirmaravirocmaribavir show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Coronavirus infection off-label use 186747009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.81 acidic
pKa2 10.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Spike glycoprotein Glycoprotein IC50 5.39 CHEMBL
Hemagglutinin [Cleaved into: Hemagglutinin HA1 chain; Hemagglutinin HA2 chain] Viral envelope protein Kd 4.96 CHEMBL

External reference:

IDSource
93M09WW4RU UNII
D10558 KEGG_DRUG
C0254211 UMLSCUI
CHEBI:134730 CHEBI
75U PDB_CHEM_ID
CHEMBL1214598 ChEMBL_ID
131411 PUBCHEM_CID
DB13609 DRUGBANK_ID
9271 INN_ID
C086979 MESH_SUPPLEMENTAL_RECORD_UI
11089 IUPHAR_LIGAND_ID

Pharmaceutical products:

None